Outlook Therapeutics, Inc. — Form 8-K
Filed August 27, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Outlook Therapeutics hired Kevin Lundquist as CFO effective September 1, 2026, at $450,000 annual base salary plus up to 50% bonus and 500,000 stock options (25% vesting at 1 year, remainder over 3 years). Simultaneously, outgoing CFO Lawrence A. Kenyon received a separation agreement with 12 months base salary (~$460K estimated), full 2026 bonus, accelerated 100% vesting of all outstanding equity, and 12 months COBRA coverage, effective September 1–30, 2026 transition period.
Why this rating
CFO replacement is routine corporate housekeeping. Combined separation + hiring costs ~$600K+ severance plus equity acceleration—material relative to $26.9M market cap (~2.2% of cap)—but typical for biotech leadership transition. No business direction change disclosed.
See more from August 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.